Nanothera Biosciences
State-of-the-art science driving disruptive biologic drug and drug delivery programs.
Most potent KRAS membrane-localization (PDEδ) inhibitor reported to date
- CCM-DS2 mechanism of action
- CCM-DS2
PI: Prof. Herbert Waldmann, Max Planck Institute
Scientific Publications:
- Martin-Gago, P. et al. A PDE6d-Kras inhibitor chemotype with up to seven H-bonds and picomolar affinity that prevents efficient inhibitor release by Arl2. Angewandte Chemie 56: 2423-2428, 2017.
- Klein, C.H. et al. PDEd inhibition impedes the proliferation and survival of human colorectal cancer cell lines harboring oncogenic KRAS. Int. J. Cancer, 144(4): 767-776, 2019.
PI: Prof. Herbert Waldmann, Max Planck Institute
Scientific Publications:
- Martin-Gago, P. et al. A PDE6d-Kras inhibitor chemotype with up to seven H-bonds and picomolar affinity that prevents efficient inhibitor release by Arl2. Angewandte Chemie 56: 2423-2428, 2017.
- Klein, C.H. et al. PDEd inhibition impedes the proliferation and survival of human colorectal cancer cell lines harboring oncogenic KRAS. Int. J. Cancer, 144(4): 767-776, 2019.
amiRNA/siRNA KRAS Gene Therapy: the most selective and potent KRAS RNAi API reported to date
- Targeting KRAS in metastatic CRC
- Intratumor injection of amiR-KS3
Identification of Novel Peptide Ligands for the EGFRvIII Receptor
- EGFRvIII-selective active targeting ligands
- FITC fluorescence intensity
PI: Dr. Raj Chakrabarti, CCM
Scientific Publications:
- Modjtahedi, H. et al. Targeting of cells expressing wild-type EGFR and type-III mutant EGFR (EGFRvIII) by anti-EGFR Mab ICR62: a two-pronged attack for tumour therapy, Int. J. Cancer 105: 273-280, 2003.
- Kuan, C-T. et al. EGF mutant receptor vIII as a molecular target in cancer, Endocr. Relat. Cancer 8: 83-96, 2001
PI: Dr. Raj Chakrabarti, CCM
Scientific Publications:
- Modjtahedi, H. et al. Targeting of cells expressing wild-type EGFR and type-III mutant EGFR (EGFRvIII) by anti-EGFR Mab ICR62: a two-pronged attack for tumour therapy, Int. J. Cancer 105: 273-280, 2003.
- Kuan, C-T. et al. EGF mutant receptor vIII as a molecular target in cancer, Endocr. Relat. Cancer 8: 83-96, 2001
CCM-7314 outperforms all reported anti-inflammation drug candidates for NASH/AH in preclinical models
